Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: Preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 9, 2002, Pages 50-54

  Sederholm, Christer ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEMATURIA; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SWEDEN; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VOMITING;

EID: 0036317824     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.34276     Document Type: Conference Paper

References (11)

1. A phase II study of gemcitabine plus carboplatin in chemonaive patients with advanced non-small cell lung cancer (NSCLC)
2. Gemcitabine: Single-agent and combination therapy in non-small cell lung cancer
3. Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer
4. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study
5. Single-agent gemcitabine: An active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer
6. Gemcitabine monotherapy (GEM) versus cisplatin-based chemotherapy in symptomatic advanced NSCLC: A prospective randomised comparison of symptom control
7. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group
8. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861
9. Randomized pan-European trial comparing paclitaxel/carboplatin versus paclitaxel/cisplatin in advanced non-small cell lung cancer
10. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: A randomized phase III study
11. Chemotherapy for stage IV non-small cell lung cancer